Stock Events

Stock Events

Rezolute 

€3.28
38
+€0.04+1.23% Today

Statistics

Day High
3.36
Day Low
3.18
52W High
3.92
52W Low
2.52
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10SepExpected
Q4 2025
Q1 2026
Next
-0.19
-0.17
-0.15
-0.13
Expected EPS
-0.12818595000000002
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6HV1.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap40.46B
Alnylam Pharmaceuticals, Inc. operates in the biopharmaceutical field focusing on RNAi therapeutics for the treatment of rare genetic diseases, competing in the same rare disease space as Rezolute.
Ionis Pharmaceuticals
IONS
Mkt Cap12.31B
Ionis Pharmaceuticals, Inc. develops RNA-targeted therapeutics, directly competing with Rezolute's approach to treating rare diseases through innovative therapies.
Viking Therapeutics
VKTX
Mkt Cap3.3B
Viking Therapeutics, Inc. is involved in the development of therapies for metabolic and endocrine disorders, directly competing with Rezolute's metabolic disease focus.
Seres Therapeutics
MCRB
Mkt Cap64.2M
Seres Therapeutics, Inc. is engaged in microbiome therapeutics for metabolic diseases, which places it in direct competition with Rezolute's metabolic disease treatments.
PTC Therapeutics
PTCT
Mkt Cap5.88B
PTC Therapeutics, Inc. focuses on the discovery and commercialization of novel medicines to treat rare disorders, directly competing with Rezolute in the rare disease market.
Sarepta Therapeutics
SRPT
Mkt Cap1.66B
Sarepta Therapeutics, Inc. specializes in the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases, competing in the rare disease space alongside Rezolute.

About

Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for metabolic conditions marked by persistent glucose imbalances, primarily serving the United States market. Its flagship product candidate, RZ358, a human monoclonal antibody, is currently progressing through Phase 2b clinical trials as a potential treatment for congenital hyperinsulinism, an exceptionally rare genetic disorder impacting pediatric patients. The company is also developing RZ402, a powerful and selective plasma kallikrein inhibitor, which is in Phase 1 clinical evaluation for the ongoing management of diabetic macular edema. Founded in 2010, the entity was formerly known as AntriaBio, Inc. before adopting the Rezolute, Inc. name in December 2017, and its operations are based out of Redwood City, California.
Show more...
CEO
ISIN
US76200L3096

Listings

F
DE
6HV1.F
STU
DE
6HV1.STU
MU
DE
6HV1.MU
XNAS
US
RZLT

0 Comments

Share your thoughts

FAQ

What is Rezolute stock price today?▼
The current price of 6HV1.STU is €3.28 EUR — it has increased by +1.23% in the past 24 hours. Watch Rezolute stock price performance more closely on the chart.
What is Rezolute stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Rezolute stocks are traded under the ticker 6HV1.STU.
When is the next Rezolute earnings date?▼
Rezolute is going to release the next earnings report on September 10, 2026.
What were Rezolute earnings last quarter?▼
6HV1.STU earnings for the last quarter are -0.14 EUR per share, whereas the estimation was -0.15 EUR resulting in a +11.5% surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is Rezolute located?▼
Rezolute operates in the Other sector.
When did Rezolute complete a stock split?▼
Rezolute has not had any recent stock splits.